Patent ID: 9732139
Date: 2017-08-15
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method of treating cancer in a human subject in need thereof, the method comprising administering to the subject a soluble receptor comprising (a) a fragment of an extracellular domain of a human Frizzled (FZD) receptor and (b) a human Fc domain, wherein: (i) the fragment of the extracellular domain of the human FZD receptor consists essentially of the Fri domain of the human FZD receptor; (ii) the soluble receptor has a longer half-life in vivo than a soluble receptor comprising the extracellular domain of the FZD receptor and the human Fc, domain; and (iii) the cancer is selected from the group consisting of pancreatic cancer, ovarian cancer, hepatocellular cancer, breast cancer, colorectal cancer, lung cancer, prostate cancer, and head and neck cancer.